Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | SHBG | P04278 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31076513 | 0.81 | — | — | |
| SCHEMBL22452366 | 0.78 | ACHE (0.37) | HSD17B10ALOX15TSHRACHESHBG | |
| SCHEMBL9369186 | 0.78 | ACHE (0.37) | HSD17B10ALOX15TSHRACHESHBG | |
| SCHEMBL26851762 | 0.77 | ACHE (0.41) | HSD17B10ALOX15ACHESHBGALDH1A1 | |
| SCHEMBL3310038 | 0.75 | ALOX15 (0.38) | HSD17B10ALOX15TSHRACHESHBG | |
| SCHEMBL2459165 | 0.75 | ACHE (0.42) | HSD17B10ALOX15TSHRACHESHBG | |
| SCHEMBL879829 | 0.75 | ACHE (0.42) | HSD17B10ALOX15TSHRACHESHBG | |
| SCHEMBL31618730 | 0.71 | CYP3A4 (0.42) | ALOX15ACHEALDH1A1 | |
| SCHEMBL6478847 | 0.70 | RAPGEF4 (0.36) | LMNAALDH1A1 | |
| SCHEMBL12699692 | 0.70 | CYP3A4 (0.38) | ALOX15TSHRLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4642778-A1 | LSD1 MODULATORS | Recursion Pharmaceuticals, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| WO-2024141757-A1 | LSD1 MODULATORS | EXSCIENTIA AI LIMITED (GB) | 2024-07-04 | — | — | WO | disclosed |